Sofia Dinegro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sofia Dinegro has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Stefania Cheli
Pharmacovigilance & Clinical Research, International Centre for Pesticides and Health Risk Prevention, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20157 Milan, Italy
4 shared publications - Carla Carnovale
Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università Degli Studi Di Milano, Milan, Italy
3 shared publications - Ilaria Mariani
Pharmacovigilance & Clinical Research, International Centre for Pesticides and Health Risk Prevention, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20157 Milan, Italy
3 shared publications - Vera Battini
Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of BioPharmacovigilance & Clinical Research, Intmedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Italy
3 shared publications - Andrea Gori
Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital , Milan
2 shared publications Emilio Clementi
ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, University Hospital Luigi Sacco, ASST Fatebenefratelli Sacco, Università degli Studi di Milano, Italy
2 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 749
Real-World Patterns of Delayed Cutaneous Adverse Reactions to Antimicrobial Therapy in Children: A Case Series and FAERS Analysis Across Age Groups
Background/Objectives: Cutaneous adverse drug reactions (CADRs) account for approximately 45% of all adverse drug reactions. Although most are self-limiting, some may progress to severe cutaneous adverse reactions (SCARs). In children, delayed rashes associated with antimicrobial therapy, particularly beta-lactams, are often misclassified as drug allergies, leading to unnecessary antibiotic avoidance and potentially suboptimal antimicrobial prescribing. This study aimed to characterize delayed antimicrobial-associated CADRs in children and to investigate reporting patterns and factors associated with their clinical management across age groups. Methods: Real-world data from pediatric patients hospitalized in 2023 at the “Ospedale dei Bambini Vittore Buzzi” (Milan, Italy) were integrated with Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS). Only cases with documented treatment durations were included. Clinical characteristics, antimicrobial exposure patterns, and factors associated with the reporting of delayed rashes were evaluated. Results: Five pediatric patients developed delayed CADRs after 19–22 days of antimicrobial therapy. Infectious and immunological investigations were negative, and symptoms resolved following drug discontinuation. FAERS analysis identified 97 delayed rash reports, associated with prolonged treatment duration, frequent polytherapy, and higher reporting rates for vancomycin, teicoplanin, and beta-lactam combination regimens. Logistic regression showed that age and polypharmacy were significantly associated with reporting patterns of delayed rash and therapy continuation among reported cases. Conclusions: Among reported cases, delayed antimicrobial-associated CADRs were associated with age and polypharmacy. Improved recognition of these reactions may facilitate appropriate clinical management, support more informed prescribing decisions, and reduce inappropriate antibiotic allergy labeling. Further studies are needed to validate these findings and refine risk-based management strategies in pediatric patients.
- 3 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 749
Open AccessReal-World Patterns of Delayed Cutaneous Adverse Reactions to Antimicrobial Therapy in Children: A Case Series and FAERS Analysis Across Age Groups
Background/Objectives: Cutaneous adverse drug reactions (CADRs) account for approximately 45% of all adverse drug reactions. Although most are self-limiting, some may progress to severe cutaneous adverse reactions (SCARs). In children, delayed rashes associated with antimicrobial therapy, particularly beta-lactams, are often misclassified as drug allergies, leading to unnecessary antibiotic avoidance and potentially suboptimal antimicrobial prescribing. This study aimed to characterize delayed antimicrobial-associated CADRs in children and to investigate reporting patterns and factors associated with their clinical management across age groups. Methods: Real-world data from pediatric patients hospitalized in 2023 at the “Ospedale dei Bambini Vittore Buzzi” (Milan, Italy) were integrated with Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS). Only cases with documented treatment durations were included. Clinical characteristics, antimicrobial exposure patterns, and factors associated with the reporting of delayed rashes were evaluated. Results: Five pediatric patients developed delayed CADRs after 19–22 days of antimicrobial therapy. Infectious and immunological investigations were negative, and symptoms resolved following drug discontinuation. FAERS analysis identified 97 delayed rash reports, associated with prolonged treatment duration, frequent polytherapy, and higher reporting rates for vancomycin, teicoplanin, and beta-lactam combination regimens. Logistic regression showed that age and polypharmacy were significantly associated with reporting patterns of delayed rash and therapy continuation among reported cases. Conclusions: Among reported cases, delayed antimicrobial-associated CADRs were associated with age and polypharmacy. Improved recognition of these reactions may facilitate appropriate clinical management, support more informed prescribing decisions, and reduce inappropriate antibiotic allergy labeling. Further studies are needed to validate these findings and refine risk-based management strategies in pediatric patients.
- 31 May 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (8) , 1168-1176
Fever in a palliative care setting: Clinical insights and implications from a prospective observational cohort study
Background: Fever is a frequent but complex symptom in adults with a limited prognosis, arising from multifactorial causes beyond infection. Despite its impact on symptom burden and therapeutic decision-making, evidence from inpatient palliative care settings is limited. Aim: To assess the prevalence, characteristics, and associated factors of fever in adults with a limited prognosis receiving inpatient hospice palliative care in order to enhance understanding of this symptom in palliative care settings. Design: Prospective observational cohort study. Collected data included demographic and clinical variables, symptom burden, potential risk factors for infections (such as presence of medical devices and pressure injuries), and fever occurrence. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of fever. Setting/participants: The study was conducted in an inpatient hospice palliative care unit within the Luigi Sacco Hospital in Milan, Italy (January and December 2024). A total of 145 adults with a limited prognosis were enrolled. Results: Fever occurred in 40% of patients, with a median onset of 5.5 days after admission. In 39.7% of cases, fever was attributed to infections, mainly catheter-associated urinary tract infection. Medical devices, particularly bladder catheters (89.7%), were strongly associated with fever (adjusted odds ratio: 12.42; confidence interval: 2.39–64.57). Conclusions: Fever is common among adults receiving inpatient hospice palliative care and is infection-related in about 40% of cases. Its strong association with medical devices highlights the need for proportional, personalised interventions that primarily consider prognosis, symptom relief, and quality of life. Registration: ClinicalTrials.gov ID NCT07106073
- 31 May 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (8) , 1168-1176
Fever in a palliative care setting: Clinical insights and implications from a prospective observational cohort study
Background: Fever is a frequent but complex symptom in adults with a limited prognosis, arising from multifactorial causes beyond infection. Despite its impact on symptom burden and therapeutic decision-making, evidence from inpatient palliative care settings is limited. Aim: To assess the prevalence, characteristics, and associated factors of fever in adults with a limited prognosis receiving inpatient hospice palliative care in order to enhance understanding of this symptom in palliative care settings. Design: Prospective observational cohort study. Collected data included demographic and clinical variables, symptom burden, potential risk factors for infections (such as presence of medical devices and pressure injuries), and fever occurrence. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of fever. Setting/participants: The study was conducted in an inpatient hospice palliative care unit within the Luigi Sacco Hospital in Milan, Italy (January and December 2024). A total of 145 adults with a limited prognosis were enrolled. Results: Fever occurred in 40% of patients, with a median onset of 5.5 days after admission. In 39.7% of cases, fever was attributed to infections, mainly catheter-associated urinary tract infection. Medical devices, particularly bladder catheters (89.7%), were strongly associated with fever (adjusted odds ratio: 12.42; confidence interval: 2.39–64.57). Conclusions: Fever is common among adults receiving inpatient hospice palliative care and is infection-related in about 40% of cases. Its strong association with medical devices highlights the need for proportional, personalised interventions that primarily consider prognosis, symptom relief, and quality of life. Registration: ClinicalTrials.gov ID NCT07106073
- 6 September 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 342-347
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)
Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 – 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 – 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.
- 6 September 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 342-347
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)
Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 – 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 – 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.
- Open Access
- 19 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3881
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
Antituberculosis drug-induced hepatotoxicity (ATDH) is a common adverse drug reaction often requiring treatment interruption, complicating tuberculosis management. The slow acetylator phenotype, characterized by reduced N-acetyltransferase 2 (NAT2) enzyme activity, is associated with increased hepatotoxicity risk, while rapid acetylators are associated with a higher risk of therapeutic failure. This study investigates the association between the NAT2 acetylation phenotype and ATDH occurrence, with an emphasis on its predictive value in regard to a multiethnic population and its impact on the timing of ATDH onset. A retrospective observational study was conducted on tuberculosis patients treated at Luigi Sacco Hospital, Milan, Italy (July 2020–September 2023). The NAT2 genotyping identified slow and rapid/intermediate acetylators. Cumulative incidence analysis and Fine–Gray competing risks regression models were used to assess ATDH risk and onset timing. Among 102 patients, 21.6% developed ATDH, including 16.7% with slow and 4.9% with rapid/intermediate acetylators. ATDH onset was significantly earlier in regard to slow acetylators (median 0.5 vs. 2 months, interquartile range-IQR: 0.5–3 vs. 1.7–5.5). Slow acetylators were associated with a higher risk of developing ATDH (Sub-distribution hazard ratio, SHR = 3.05; 95% confidence interval-CI: 1.17–7.95; p = 0.02), even after adjusting for confounders. The NAT2 acetylation phenotype strongly influences ATDH risk and timing. Early acetylator status identification may enable dose adjustments, enhancing treatment safety. These findings highlight the role of pharmacogenetics in optimizing antituberculosis therapy by improving efficacy and minimizing toxicity.
- 19 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3881
Open AccessNAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
Antituberculosis drug-induced hepatotoxicity (ATDH) is a common adverse drug reaction often requiring treatment interruption, complicating tuberculosis management. The slow acetylator phenotype, characterized by reduced N-acetyltransferase 2 (NAT2) enzyme activity, is associated with increased hepatotoxicity risk, while rapid acetylators are associated with a higher risk of therapeutic failure. This study investigates the association between the NAT2 acetylation phenotype and ATDH occurrence, with an emphasis on its predictive value in regard to a multiethnic population and its impact on the timing of ATDH onset. A retrospective observational study was conducted on tuberculosis patients treated at Luigi Sacco Hospital, Milan, Italy (July 2020–September 2023). The NAT2 genotyping identified slow and rapid/intermediate acetylators. Cumulative incidence analysis and Fine–Gray competing risks regression models were used to assess ATDH risk and onset timing. Among 102 patients, 21.6% developed ATDH, including 16.7% with slow and 4.9% with rapid/intermediate acetylators. ATDH onset was significantly earlier in regard to slow acetylators (median 0.5 vs. 2 months, interquartile range-IQR: 0.5–3 vs. 1.7–5.5). Slow acetylators were associated with a higher risk of developing ATDH (Sub-distribution hazard ratio, SHR = 3.05; 95% confidence interval-CI: 1.17–7.95; p = 0.02), even after adjusting for confounders. The NAT2 acetylation phenotype strongly influences ATDH risk and timing. Early acetylator status identification may enable dose adjustments, enhancing treatment safety. These findings highlight the role of pharmacogenetics in optimizing antituberculosis therapy by improving efficacy and minimizing toxicity.